Nuclear Factor-κB modulates cellular glutathione and prevents oxidative stress in cancer cells

Cancer Letters

Volumn 299, Issue 1, 2010, Pages 45-53

  Meng, Qinghang ^a   Peng, Zhimin ^a,c   Chen, Liang ^a   Si, Jutong ^b   Dong, Zhongyun ^a   Xia, Ying ^a  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^b Fred Hutchinson Cancer Research Center   (United States)

^c UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

Arsenic; Glutathione; Leukemia; NF B; Oxidative stress; Prostate cancer

Indexed keywords

GLUTATHIONE; I KAPPA B; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; SCAVENGER; ARSENIC TRIOXIDE; ORGANOARSENIC DERIVATIVE; OXIDE;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CANCER CELL; CANCER CELL CULTURE; CELL DEATH; CELL LEVEL; CELL STRAIN LNCAP; CONTROLLED STUDY; DOWN REGULATION; EMBRYO; FIBROBLAST CULTURE; HUMAN; HUMAN CELL; LEUKEMIA CELL; MOUSE; MYELOID LEUKEMIA; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN ANALYSIS; PROTEIN FUNCTION; PROTEIN SYNTHESIS; ANIMAL; ANTAGONISTS AND INHIBITORS; LEUKEMIA; MALE; METABOLISM; PATHOLOGY; PHYSIOLOGY; PROSTATIC NEOPLASMS; SIGNAL TRANSDUCTION;

ANIMALS; ARSENICALS; GLUTATHIONE; HUMANS; LEUKEMIA; MALE; MICE; NF-KAPPA B; OXIDATIVE STRESS; OXIDES; PROSTATIC NEOPLASMS; SIGNAL TRANSDUCTION;

EID: 77957930428     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2010.08.002     Document Type: Article

References (42)

1. Pahl H.L. Activators and target genes of Rel/NF-kappaB transcription factors. Oncogene 1999, 18:6853-6866.
2. Pikarsky E., Porat R.M., Stein I., Abramovitch R., Amit S., Kasem S., Gutkovich-Pyest E., Urieli-Shoval S., Galun E., Ben-Neriah Y. NF-kappaB functions as a tumour promoter in inflammation-associated cancer. Nature 2004, 431:461-466.
3. Pham C.G., Bubici C., Zazzeroni F., Papa S., Jones J., Alvarez K., Jayawardena S., De S.E., Cong R., Beaumont C., Torti F.M., Torti S.V., Franzoso G. Ferritin heavy chain upregulation by NF-kappaB inhibits TNFalpha-induced apoptosis by suppressing reactive oxygen species. Cell 2004, 119:529-542.
4. Chen F., Castranova V., Li Z., Karin M., Shi X. Inhibitor of nuclear factor kappaB kinase deficiency enhances oxidative stress and prolongs c-Jun NH2-terminal kinase activation induced by arsenic. Cancer Res. 2003, 63:7689-7693.
5. Peng Z., Peng L., Fan Y., Zandi E., Shertzer H.G., Xia Y. A critical role for IkappaB kinase beta in metallothionein-1 expression and protection against arsenic toxicity. J. Biol. Chem. 2007, 282:21487-21496.
6. Luo J.L., Kamata H., Karin M. IKK/NF-kappaB signaling: balancing life and death - a new approach to cancer therapy. J. Clin. Invest. 2005, 115:2625-2632.
7. Peng Z., Geh E., Chen L., Meng Q., Fan Y., Sartor M., Shertzer H.G., Liu Z.G., Puga A., Xia Y. Inhibitor of {kappa}B kinase {beta} regulates redox homeostasis by controlling the constitutive levels of glutathione. Mol. Pharmacol. 2010, 77:784-792.
8. Meister A., Anderson M.E. Glutathione. Annu. Rev. Biochem. 1983, 52:711-760.
9. Sierra-Rivera E., Meredith M.J., Summar M.L., Smith M.D., Voorhees G.J., Stoffel C.M., Freeman M.L. Genes regulating glutathione concentrations in X-ray-transformed rat embryo fibroblasts: changes in gamma-glutamylcysteine synthetase and gamma-glutamyltranspeptidase expression. Carcinogenesis 1994, 15:1301-1307.
10. Guzman M.L., Neering S.J., Upchurch D., Grimes B., Howard D.S., Rizzieri D.A., Luger S.M., Jordan C.T. Nuclear factor-kappaB is constitutively activated in primitive human acute myelogenous leukemia cells. Blood 2001, 98:2301-2307.
11. Barbarroja N., Ristides-Torres L., Hernandez V., Martin C., Dorado G., Torres A., Velasco F., Lopez-Pedrera C. Coordinated deregulation of cellular receptors, proangiogenic factors and intracellular pathways in acute myeloid leukaemia. Leukemia Lymphoma 2007, 48:1187-1199.
12. Birkenkamp K.U., Geugien M., Schepers H., Westra J., Lemmink H.H., Vellenga E. Constitutive NF-kappaB DNA-binding activity in AML is frequently mediated by a Ras/PI3-K/PKB-dependent pathway. Leukemia 2004, 18:103-112.
13. Bueso-Ramos C.E., Rocha F.C., Shishodia S., Medeiros L.J., Kantarjian H.M., Vadhan-Raj S., Estrov Z., Smith T.L., Nguyen M.H., Aggarwal B.B. Expression of constitutively active nuclear-kappa B RelA transcription factor in blasts of acute myeloid leukemia. Hum. Pathol. 2004, 35:246-253.
14. Suh J., Payvandi F., Edelstein L.C., Amenta P.S., Zong W.X., Gelinas C., Rabson A.B. Mechanisms of constitutive NF-kappaB activation in human prostate cancer cells. Prostate 2002, 52:183-200.
15. Palayoor S.T., Youmell M.Y., Calderwood S.K., Coleman C.N., Price B.D. Constitutive activation of IkappaB kinase alpha and NF-kappaB in prostate cancer cells is inhibited by ibuprofen. Oncogene 1999, 18:7389-7394.
16. Karin M., Greten F.R. NF-kappaB: linking inflammation and immunity to cancer development and progression. Nat. Rev. Immunol. 2005, 5:749-759.
17. Stephenson R.A., Dinney C.P., Gohji K., Ordonez N.G., Killion J.J., Fidler I.J. Metastatic model for human prostate cancer using orthotopic implantation in nude mice. J. Natl. Cancer Inst. 1992, 84:951-957.
18. Collins S.J., Robertson K.A., Mueller L. Retinoic acid-induced granulocytic differentiation of HL-60 myeloid leukemia cells is mediated directly through the retinoic acid receptor (RAR-alpha). Mol. Cell Biol. 1990, 10:2154-2163.
19. Tojima Y., Fujimoto A., Delhase M., Chen Y., Hatakeyama S., Nakayama K., Kaneko Y., Nimura Y., Motoyama N., Ikeda K., Karin M., Nakanishi M. NAK is an IkappaB kinase-activating kinase. Nature 2000, 404:778-782.
20. Yang H., Wang J., Ou X., Huang Z.Z., Lu S.C. Cloning and analysis of the rat glutamate-cysteine ligase modifier subunit promoter. Biochem. Biophys. Res. Commun. 2001, 285:476-482.
21. Yang H., Wang J., Huang Z.Z., Ou X., Lu S.C. Cloning and characterization of the 5'-flanking region of the rat glutamate-cysteine ligase catalytic subunit. Biochem. J. 2001, 357:447-455.
22. Senft A.P., Dalton T.P., Shertzer H.G. Determining glutathione and glutathione disulfide using the fluorescence probe o-phthalaldehyde. Anal. Biochem. 2000, 280:80-86.
23. Dalton T.P., Chen Y., Schneider S.N., Nebert D.W., Shertzer H.G. Genetically altered mice to evaluate glutathione homeostasis in health and disease. Free Radical Biol. Med. 2004, 37:1511-1526.
24. Melisi D., Chiao P.J. NF-kappa B as a target for cancer therapy. Expert. Opin. Ther. Targets 2007, 11:133-144.
25. Savickiene J., Treigyte G., Pivoriunas A., Navakauskiene R., Magnusson K.E. Sp1 and NF-kappaB transcription factor activity in the regulation of the p21 and FasL promoters during promyelocytic leukemia cell monocytic differentiation and its associated apoptosis. Ann. NY Acad. Sci. 2004, 1030:569-577.
26. Kerbauy D.M., Lesnikov V., Abbasi N., Seal S., Scott B., Deeg H.J. NF-kappaB and FLIP in arsenic trioxide (ATO)-induced apoptosis in myelodysplastic syndromes (MDSs). Blood 2005, 106:3917-3925.
27. Assef Y., Rubio F., Colo G., del M.S., Costas M.A., Kotsias B.A. Imatinib resistance in multidrug-resistant K562 human leukemic cells. Leukemia Res. 2009, 33:710-716.
28. Moon D.O., Kim M.O., Kang S.H., Choi Y.H., Kim G.Y. Sulforaphane suppresses TNF-alpha-mediated activation of NF-kappaB and induces apoptosis through activation of reactive oxygen species-dependent caspase-3. Cancer Lett. 2009, 274:132-142.
29. Zhou G.B., Li G., Chen S.J., Chen Z. From dissection of disease pathogenesis to elucidation of mechanisms of targeted therapies: leukemia research in the genomic era. Acta Pharmacol. Sin. 2007, 28:1434-1449.
30. Wang Z.Y. Ham-Wasserman lecture: treatment of acute leukemia by inducing differentiation and apoptosis. Hematology. Am. Soc. Hematol. Educ. Program 2003, 45:1-13.
31. Soignet S.L. Clinical experience of arsenic trioxide in relapsed acute promyelocytic leukemia. Oncologist 2001, 2(6 Suppl.):11-16.
32. Anderson M.E. Glutathione: an overview of biosynthesis and modulation. Chem. Biol. Interact. 1998, 111-112:1-14.
33. Aggarwal B.B., Shishodia S. Suppression of the nuclear factor-kappaB activation pathway by spice-derived phytochemicals: reasoning for seasoning. Ann. NY Acad. Sci. 2004, 1030:434-441.
34. Gasparian A.V., Yao Y.J., Kowalczyk D., Lyakh L.A., Karseladze A., Slaga T.J., Budunova I.V. The role of IKK in constitutive activation of NF-kappaB transcription factor in prostate carcinoma cells. J. Cell Sci. 2002, 115:141-151.
35. Kim H.J., Hawke N., Baldwin A.S. NF-kappaB and IKK as therapeutic targets in cancer. Cell Death. Differ. 2006, 13:738-747.
36. Davison K., Mann K.K., Miller W.H. Arsenic trioxide: mechanisms of action. Semin. Hematol. 2002, 39:3-7.
37. Jing Y., Dai J., Chalmers-Redman R.M., Tatton W.G., Waxman S. Arsenic trioxide selectively induces acute promyelocytic leukemia cell apoptosis via a hydrogen peroxide-dependent pathway. Blood 1999, 94:2102-2111.
38. Miyajima A., Nakashima J., Yoshioka K., Tachibana M., Tazaki H., Murai M. Role of reactive oxygen species in cis-dichlorodiammineplatinum-induced cytotoxicity on bladder cancer cells. Br. J. Cancer 1997, 76:206-210.
39. Ravi R., Bedi A. NF-kappaB in cancer - a friend turned foe. Drug Resist. Update 2004, 7:53-67.
40. Huang S., Robinson J.B., Deguzman A., Bucana C.D., Fidler I.J. Blockade of nuclear factor-kappaB signaling inhibits angiogenesis and tumorigenicity of human ovarian cancer cells by suppressing expression of vascular endothelial growth factor and interleukin 8. Cancer Res. 2000, 60:5334-5339.
41. Guttridge D.C., Albanese C., Reuther J.Y., Pestell R.G., Baldwin A.S. NF-kappaB controls cell growth and differentiation through transcriptional regulation of cyclin D1. Mol. Cell Biol. 1999, 19:5785-5799.
42. Bourguignon L.Y., Xia W., Wong G. Hyaluronan-mediated CD44 interaction with p300 and SIRT1 regulates beta-catenin signaling and NFkappaB-specific transcription activity leading to MDR1 and Bcl-xL gene expression and chemoresistance in breast tumor cells. J. Biol. Chem. 2009, 284:2657-2671.